Mohammad Hirmand
About
Mohammad Hirmand is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology.
According to data from OpenAlex, Mohammad Hirmand has authored 38 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Pulmonary and Respiratory Medicine, 22 papers in Radiology, Nuclear Medicine and Imaging and 16 papers in Oncology. Recurrent topics in Mohammad Hirmand's work include Prostate Cancer Treatment and Research (33 papers), Radiopharmaceutical Chemistry and Applications (21 papers) and Cancer Treatment and Pharmacology (11 papers). Mohammad Hirmand is often cited by papers focused on Prostate Cancer Treatment and Research (33 papers), Radiopharmaceutical Chemistry and Applications (21 papers) and Cancer Treatment and Pharmacology (11 papers). Mohammad Hirmand collaborates with scholars based in United States, France and United Kingdom. Mohammad Hirmand's co-authors include Howard I. Scher, Karim Fizazi, Johann S. de Bono, Mary‐Ellen Taplin, Cora N. Sternberg, Lynn Seely, Fred Saad, Kurt Miller, Ronald de Wit and Andrew J. Armstrong and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.
In The Last Decade
Mohammad Hirmand
38 papers receiving 5.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mohammad Hirmand United States | 18 | 4.6k | 1.6k | 1.6k | 1.3k | 1.2k | 38 | 5.2k | ||
| Dana E. Rathkopf United States | 35 | 3.8k 0.8× | 1.3k 0.8× | 1.4k 0.9× | 1.7k 1.3× | 1.6k 1.4× | 203 | 5.3k | ||
| Thian Kheoh United States | 38 | 6.2k 1.3× | 2.3k 1.4× | 2.4k 1.4× | 2.3k 1.7× | 1.3k 1.1× | 124 | 7.6k | ||
| Bryan Selby United States | 5 | 3.3k 0.7× | 1.1k 0.7× | 1.0k 0.6× | 917 0.7× | 848 0.7× | 11 | 3.7k | ||
| Simon Chowdhury United Kingdom | 29 | 4.0k 0.9× | 1.3k 0.8× | 1.4k 0.9× | 1.4k 1.0× | 1.0k 0.9× | 199 | 5.1k | ||
| Mary Ellen Taplin United States | 16 | 4.2k 0.9× | 962 0.6× | 1.0k 0.6× | 1.6k 1.2× | 924 0.8× | 27 | 5.1k | ||
| Matthew M. Cooney United States | 24 | 3.6k 0.8× | 1.1k 0.7× | 1.1k 0.7× | 1.8k 1.4× | 1.0k 0.9× | 86 | 5.2k | ||
| Dingwei Ye China | 26 | 3.9k 0.8× | 1.3k 0.8× | 1.6k 1.0× | 1.1k 0.8× | 958 0.8× | 135 | 5.0k | ||
| J Horti Hungary | 9 | 3.6k 0.8× | 1.2k 0.7× | 1.1k 0.7× | 1.6k 1.2× | 1.0k 0.9× | 17 | 4.6k | ||
| William R. Berry United States | 11 | 3.9k 0.8× | 1.3k 0.8× | 1.1k 0.7× | 1.8k 1.3× | 985 0.8× | 22 | 4.9k | ||
| Susan Feyerabend United Kingdom | 21 | 3.2k 0.7× | 1.0k 0.6× | 1.1k 0.7× | 1.0k 0.8× | 726 0.6× | 71 | 3.9k |
Countries citing papers authored by Mohammad Hirmand
Since
Specialization
Citations
This map shows the geographic impact of Mohammad Hirmand's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohammad Hirmand with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohammad Hirmand more than expected).
Fields of papers citing papers by Mohammad Hirmand
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Mohammad Hirmand. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohammad Hirmand. The network helps show where Mohammad Hirmand may publish in the future.
Co-authorship network of co-authors of Mohammad Hirmand
This figure shows the co-authorship network connecting the top 25 collaborators of Mohammad Hirmand. A scholar is included among the top collaborators of Mohammad Hirmand based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mohammad Hirmand. Mohammad Hirmand is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Bashir, Babar, et al.. (2024). 439TiP AVZO-021-1001: A first-in-human open-label, multicenter phase I/II dose-escalation and expansion study evaluating AVZO-021 in adult patients with advanced solid tumors. Annals of Oncology. 35. S405–S405.
2.
Jonasch, Eric, et al.. (2019). An open-label phase II study to evaluate PT2977 for the treatment of von Hippel-Lindau disease-associated renal cell carcinoma.. Journal of Clinical Oncology. 37(7_suppl). TPS680–TPS680.
3.
Bono, Johann S. de, Simon Chowdhury, Susan Feyerabend, et al.. (2017). Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe. European Urology. 74(1). 37–45.
4.
Heller, Glenn, Robert McCormack, Thian Kheoh, et al.. (2017). Circulating tumor cell (CTC) number as a response endpoint in metastatic castration resistant (mCRPC) compared with PSA across five randomized phase 3 trials.. Journal of Clinical Oncology. 35(15_suppl). 5007–5007.
5.
Armstrong, Andrew J., Fred Saad, De Phung, et al.. (2017). Clinical outcomes and survival surrogacy studies of prostate‐specific antigen declines following enzalutamide in men with metastatic castration‐resistant prostate cancer previously treated with docetaxel. Cancer. 123(12). 2303–2311.
6.
Higano, Celestia S., Tomasz M. Beer, Mary-Ellen Taplin, et al.. (2015). Long-term Safety and Antitumor Activity in the Phase 1–2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer. European Urology. 68(5). 795–801.
7.
Tombal, Bertrand, Michael Borre, Per Rathenborg, et al.. (2015). Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results. European Urology. 68(5). 787–794.
8.
Bhattacharya, Suman, Mohammad Hirmand, De Phung, & Steve van Os. (2015). Development of enzalutamide for metastatic castration‐resistant prostate cancer. Annals of the New York Academy of Sciences. 1358(1). 13–27.
9.
Tombal, Bertrand, Michael Borre, Per Rathenborg, et al.. (2014). Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study. The Lancet Oncology. 15(6). 592–600.
10.
Saad, Fred, Johann S. de Bono, Neal D. Shore, et al.. (2014). Efficacy Outcomes by Baseline Prostate-specific Antigen Quartile in the AFFIRM Trial. European Urology. 67(2). 223–230.
11.
Fizazi, Karim, Howard I. Scher, Kurt Miller, et al.. (2014). Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. The Lancet Oncology. 15(10). 1147–1156.
12.
Sternberg, Cora N., Johann S. de Bono, K.N. Chi, et al.. (2014). Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. Annals of Oncology. 25(2). 429–434.
13.
Merseburger, Axel S., Howard I. Scher, Joaquim Bellmunt, et al.. (2014). Enzalutamide in E uropean and N orth A merican men participating in the AFFIRM trial. British Journal of Urology. 115(1). 41–49.
14.
Scher, Howard I., Karim Fizazi, Fred Saad, et al.. (2013). Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor.. Journal of Clinical Oncology. 31(6_suppl). 6–6.
15.
Scher, Howard I., Karim Fizazi, Fred Saad, et al.. (2012). Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. New England Journal of Medicine. 367(13). 1187–1197.
16.
Scher, Howard I., Karim Fizazi, Fred Saad, et al.. (2012). Association of Baseline Corticosteroid with Outcomes in a Multivariate Analysis of the Phase 3 Affirm Study of Enzalutamide (ENZA), An Androgen Receptor Signaling Inhibitor (ARSI). Annals of Oncology. 23. ix297–ix297.
17.
Scher, Howard I., Karim Fizazi, Fred Saad, et al.. (2012). Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study.. Journal of Clinical Oncology. 30(5_suppl). LBA1–LBA1.
18.
Scher, Howard I., Tomasz M. Beer, Celestia S. Higano, et al.. (2010). Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. The Lancet. 375(9724). 1437–1446.
19.
Papish, Steven W., Ramesh K. Ramanathan, Jonathan H. Pincus, Mohammad Hirmand, & Howard A. Burris. (2005). Patients rescued by crossover to rubitecan in phase III study of rubitecan capsules versus 5-FU in pancreatic cancer. Journal of Clinical Oncology. 23(16_suppl). 4165–4165.
20.
Garrett, Chris R., et al.. (2004). A Phase II study of T900607 (T607) in subjects with chemotherapy-naïve unresectable hepatocellular carcinoma (HCC). Journal of Clinical Oncology. 22(14_suppl). 4125–4125.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Dana E. Rathkopf Breakdown of academic impact, for papers by Thian Kheoh Breakdown of academic impact, for papers by Bryan Selby Breakdown of academic impact, for papers by Simon Chowdhury Breakdown of academic impact, for papers by Mary Ellen Taplin Breakdown of academic impact, for papers by Matthew M. Cooney Breakdown of academic impact, for papers by Dingwei Ye Breakdown of academic impact, for papers by J Horti Breakdown of academic impact, for papers by William R. Berry Breakdown of academic impact, for papers by Susan Feyerabend